

# William D Figg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5207826/william-d-figg-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

649  
papers

28,592  
citations

90  
h-index

148  
g-index

686  
ext. papers

32,017  
ext. citations

5.9  
avg, IF

6.81  
L-index

#	Paper	IF	Citations
649	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.. <i>Oncologist</i> , <b>2022</b> , 27, e273-e285	5.7	0
648	Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome.. <i>Cancer Biology and Therapy</i> , <b>2022</b> , 23, 136-138	4.6	1
647	Single whole genome sequencing analysis blazes the trail for precision medicine.. <i>Cancer Biology and Therapy</i> , <b>2022</b> , 23, 134-135	4.6	1
646	Lutetium-177-PSMA-617: A Vision of the Future.. <i>Cancer Biology and Therapy</i> , <b>2022</b> , 23, 186-190	4.6	1
645	Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 130-130	2.2	1
644	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 93-93	2.2	0
643	ABCG2, THE BREAST CANCER RESISTANCE PROTEIN (BCRP) <b>2022</b> , 235-256		
642	Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2022</b> , 213, 114685	3.5	
641	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclox-induced cytotoxicity in atypical teratoid/rhabdoid tumors.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 410	9.8	2
640	Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , <b>2021</b> , 9, 189-193	1.6	1
639	A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. <i>Blood</i> , <b>2021</b> , 138, 2457-2457	2.2	
638	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors <b>2021</b> , 9,		2
637	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2021</b> , 138, 1815-1815	2.2	
636	Dose Optimization of Pembrolizumab: Less May Be More. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
635	Ibrutinib's off-target mechanism: cause for dose optimization. <i>Cancer Biology and Therapy</i> , <b>2021</b> , 1-3	4.6	1
634	A Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose De-Escalation. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> ,	2.9	1
633	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer <b>2021</b> , 9,		2

632	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 209-226	5.5	15
631	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. <i>Scientific Reports</i> , <b>2021</b> , 11, 5662	4.9	
630	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3298-3306	12.9	3
629	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , <b>2021</b> , 26, 288-e541	5.7	5
628	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
627	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , <b>2021</b> , 39, 566-579.e7	24.3	24
626	Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat. <i>ChemMedChem</i> , <b>2021</b> , 16, 2082-2088	3.8	6
625	A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS5090-TPS5090	2.2	
624	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e17044-e17044	2.2	1
623	Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. <i>Scientific Reports</i> , <b>2021</b> , 11, 10765	4.9	1
622	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2021</b> , 1171, 122641	3.2	6
621	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4599-TPS4599	2.2	1
620	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreaticobiliary cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3051-3051	2.2	2
619	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS5096-TPS5096	2.2	1
618	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2021</b> , 127, 435-444	5.6	3
617	Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 141-154	3.1	2
616	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. <i>Cancer Research</i> , <b>2021</b> , 81, 1076-1086	10.1	4
615	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , <b>2021</b> , 137, 896-907	2.2	8

614	PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. <i>Oncologist</i> , <b>2021</b> , 26, e115-e129	5.7	20
613	Facebook groups for alternative treatments for cancer: advertising masquerading as community support. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 25-26	21.7	0
612	Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 81-85	2.6	2
611	On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. <i>Biochemical and Biophysical Research Communications</i> , <b>2021</b> , 534, 67-72	3.4	2
610	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	6
609	Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 915-924	6.1	6
608	The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 915-916	21.7	1
607	Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 1558-1569	6.1	3
606	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , <b>2021</b> , 68, e29282	3	2
605	Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , <b>2021</b> , 26, 729-e1493	5.7	1
604	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1678-1685	13.4	1
603	Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 2081-2095	6.6	1
602	Subcutaneous Atezolizumab: A Jab Without a Benefit.. <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> ,	2.3	1
601	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabd8077	17.5	3
600	Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs. <i>Molecules</i> , <b>2020</b> , 25,	4.8	4
599	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1769-1777	3.8	10
598	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 258-267.e1	3.3	6
597	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , <b>2020</b> , 135, 2316-2319	2.2	16

596	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1430-1442	59.2	163
595	COVID-19 Clinical Diagnostics and Testing Technology. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 857-868	5.8	53
594	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2020</b> , 374, 438-451	4.7	7
593	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1099-1109	21.7	31
592	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. <i>International Journal of Nanomedicine</i> , <b>2020</b> , 15, 991-1003	7.3	10
591	Stem cell clinics: risk of proliferation. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 205-206	21.7	3
590	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
589	Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2	
588	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. <i>Blood</i> , <b>2020</b> , 136, 43-45	2.2	6
587	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11540-11540	2.2	3
586	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11552-11552	2.2	2
585	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 105-105	2.2	3
584	BETting on next-generation bromodomain inhibitors. <i>American Journal of Clinical and Experimental Urology</i> , <b>2020</b> , 8, 129-132	1.6	
583	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3553-3553	2.2	1
582	Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques () Based on the Pharmacokinetics of Intrathecally Administered Inulin. <i>Comparative Medicine</i> , <b>2020</b> , 70, 526-531	1.6	1
581	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 704-716	12.9	12
580	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 181, 113073	3.5	6
579	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 223-230	4.6	5

578	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 827-830	3.5	6
577	Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. <i>Prostate</i> , <b>2020</b> , 80, 336-344	4.2	3
576	Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors. <i>ChemMedChem</i> , <b>2020</b> , 15, 270-273	3.7	12
575	Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. <i>Photochemistry and Photobiology</i> , <b>2020</b> , 96, 668-679	3.6	1
574	Are sex discordant outcomes in COVID-19 related to sex hormones?. <i>Seminars in Oncology</i> , <b>2020</b> , 47, 335-340	5.5	26
573	Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. <i>FASEB Journal</i> , <b>2020</b> , 34, 11395-11404	0.9	6
572	Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. <i>ACS Medicinal Chemistry Letters</i> , <b>2020</b> , 11, 1711-1716	4.3	0
571	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , <b>2020</b> , 126, 4936-4947	6.4	11
570	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2308-2318	6.1	6
569	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 884-887	4.6	0
568	Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1278-1289	6.6	4
567	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 475-486	3.5	3
566	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3672-3684	2.2	37
565	Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 782-784	4.6	
564	Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. <i>AIDS Reviews</i> , <b>2020</b> , 23, 13-27	1.5	1
563	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 1-3	4.6	6
562	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 1003-1007	3.5	5
561	Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa005	0.9	3

560	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 828-836	12.9	18
559	TMPRSS2: Potential Biomarker for COVID-19 Outcomes. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 801-807	10.7	38
558	Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?. <i>BJU International</i> , <b>2019</b> , 124, 549-550	5.6	1
557	Antibody-drug conjugates for cancer. <i>Lancet, The</i> , <b>2019</b> , 394, 793-804	40	204
556	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 599-608	7.4	53
555	Insulin potentiation therapy for cancer?. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 191-192	21.7	2
554	Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters. <i>Molecular Pharmacology</i> , <b>2019</b> , 96, 158-167	4.3	13
553	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4945-4954	12.9	47
552	Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27820	3	11
551	Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors. <i>MedChemComm</i> , <b>2019</b> , 10, 500-504	5	5
550	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212097	3.7	4
549	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. <i>Journal of Human Genetics</i> , <b>2019</b> , 64, 545-550	4.3	3
548	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4238-4247	12.9	9
547	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 759-770	3.5	2
546	PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. <i>Journal of Controlled Release</i> , <b>2019</b> , 308, 86-97	11.7	8
545	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2019</b> , 8, 247-257	4.4	8
544	A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses <b>2019</b> , 7, 197		51
543	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e349-e360	3.8	17

542	How do you take your coffee?. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 913-914	21.7	
541	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. <i>Scientific Reports</i> , <b>2019</b> , 9, 14884	4.9	1
540	A modeling and simulation study of less frequent dosing of nivolumab 480 mg.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3115-3115	2.2	5
539	A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 173-173	2.2	2
538	Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 241-241	2.2	1
537	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. <i>Oncotarget</i> , <b>2019</b> , 10, 2855-2868	3.3	7
536	Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. <i>ELife</i> , <b>2019</b> , 8,	8.9	40
535	Author response: Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates <b>2019</b> ,		2
534	Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e16554-e16554	2.2	2
533	Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV. <i>Blood</i> , <b>2019</b> , 134, 4096-4096	2.2	2
532	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , <b>2019</b> , 69, 2048-2060	11.2	41
531	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , <b>2019</b> , 30, 19-22	2.4	4
530	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 406-410	6.2	24
529	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2018</b> , 1088, 56-62	3.2	6
528	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 457-465	2.4	27
527	Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimides for nitrite, TNF- $\alpha$ and angiogenesis inhibitory activities. <i>Bioorganic and Medicinal Chemistry</i> , <b>2018</b> , 26, 1547-1559	3.4	9
526	Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>Carcinogenesis</i> , <b>2018</b> , 39, 125-133	4.6	10
525	CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos. <i>Journal of Anatomy</i> , <b>2018</b> , 232, 568-574	2.9	4



524	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918776920	5.4	7
523	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , <b>2018</b> , 9, 2705	17.4	62
522	Revisiting 5 $\alpha$ -reductase inhibitors and the risk of prostate cancer. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 400-404	5.9	6
521	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1694-1704	6.1	22
520	The effect of an adenosine A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , <b>2018</b> , 15, 2	7	36
519	Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides. <i>ChemMedChem</i> , <b>2018</b> , 13, 2080-2089	3.7	3
518	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3333-3340	15.9	32
517	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow-up. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1389-1395	2.2	2
516	Association Between Thiopurine S-Methyltransferase ( <i>h</i> ) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 106-110	1.6	3
515	A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS11586-TPS11586	2.2	
514	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 97-100	4.6	
513	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1389-1395	2.2	89
512	Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32. <i>Drug Metabolism Letters</i> , <b>2018</b> , 12, 153	2.1	
511	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1781-1783	13.4	25
510	Reviewing the role of healthy volunteer studies in drug development. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 336	8.5	18
509	Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models. <i>Marine Drugs</i> , <b>2018</b> , 16,	6	12
508	Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 953-955	4.6	1
507	Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 869-870	4.6	1

506	Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. <i>Cytokine</i> , <b>2018</b> , 108, 213-224	4	14
505	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 565-570	3.5	5
504	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 77-85	3.3	33
503	Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 69, 553-554	7.4	4
502	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 215-218	3.5	1
501	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 203-204	4.6	1
500	Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 159-163	1.9	16
499	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 1096-1105	6.6	10
498	A new predictive tool for postoperative radiotherapy in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 277-278	4.6	
497	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 217-221	3.5	1
496	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4633-4641	12.9	56
495	Cellular identity crisis: Antiandrogen resistance by lineage plasticity. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 841-842	4.6	4
494	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , <b>2017</b> , 22, 505-511	3.7	14
493	Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 165-175	3.5	4
492	Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 132, 401-407	4.8	10
491	Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7437-7439	12.9	0
490	Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. <i>Journal of Controlled Release</i> , <b>2017</b> , 268, 147-158	11.7	36
489	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2188-2200	2.2	159

488	Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57 Suppl 10, S67-S77	2.9	14
487	Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2017</b> , 44, 521-536	2.7	8
486	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 645-652	3.5	42
485	Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 545-546	4.6	2
484	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. <i>Cancer Biology and Therapy</i> , <b>2017</b> , 18, 470-472	4.6	4
483	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 545-551	13.4	407
482	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1397-1406	12.9	32
481	A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 132, 223-226	3.5	
480	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 639-645	1.9	8
479	Vertebrate embryos as tools for anti-angiogenic drug screening and function. <i>Reproductive Toxicology</i> , <b>2017</b> , 70, 49-59	3.4	7
478	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , <b>2017</b> , 1, 1911-1918	7.8	31
477	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 2326-2338	15.9	29
476	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15786-e15786	2.2	7
475	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 176-176	2.2	7
474	Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 79175-79187	3.3	28
473	Tremelimumab: A monoclonal antibody against CTLA-4 in combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 88-88 <sup>2-2</sup>		
472	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1197-210	12.9	21
471	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1979-1986	2.6	2

470	ANG1005 for breast cancer brain metastases: correlation between F-FLT-PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 160, 51-59	4.4	23
469	Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. <i>Journal of Organic Chemistry</i> , <b>2016</b> , 81, 10631-10640	4.2	25
468	Pharmacogenomics and histone deacetylase inhibitors. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1807-1815	2.6	21
467	Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. <i>Scientific Reports</i> , <b>2016</b> , 6, 30038	4.9	27
466	Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids. <i>ChemMedChem</i> , <b>2016</b> , 11, 2621-2629	3.7	7
465	Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. <i>Cancer</i> , <b>2016</b> , 122, 588-597	6.4	57
464	UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 450-60	2.9	13
463	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 653-9	3.6	7
462	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2016</b> , 118, 590-7	5.6	19
461	The ABCG2 Multidrug Transporter <b>2016</b> , 195-226		9
460	Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 175-82	2.8	20
459	UGT genotyping in belinostat dosing. <i>Pharmacological Research</i> , <b>2016</b> , 105, 22-7	10.2	9
458	Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 467-9	4.6	3
457	Resisting resistance: Establishing new treatment options for CRPC patients. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 337-8	4.6	
456	The canSAR data hub for drug discovery. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 286	21.7	4
455	Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of a Phase 2 Study. <i>Blood</i> , <b>2016</b> , 128, 3886-3892	2.2	1
454	Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study. <i>Blood</i> , <b>2016</b> , 128, 4527-4527	2.2	4
453	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152007	3.7	17

452	Using Epigenetic Therapy to Overcome Chemotherapy Resistance. <i>Anticancer Research</i> , <b>2016</b> , 36, 1-4	2.3	22
451	In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. <i>Oncotarget</i> , <b>2016</b> , 7, 33237-45	3.3	29
450	The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. <i>Translational Cancer Research</i> , <b>2016</b> , 5, S1107-S1110	0.3	14
449	Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. <i>Separations</i> , <b>2016</b> , 3,	3.1	4
448	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 1484-1499	2.9	57
447	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 461-73	2.9	26
446	Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. <i>Cancer</i> , <b>2016</b> , 122, 2332-40	6.4	14
445	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 1648-57	7.5	40
444	Building a hit list for the fight against metastatic castration resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 231-2	4.6	4
443	Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1/ p300 Interaction. <i>Journal of Natural Products</i> , <b>2016</b> , 79, 1267-75	4.9	31
442	Synthesis of a stable and orally bioavailable englerin analogue. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2016</b> , 26, 2641-4	2.9	7
441	YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 592-4	4.6	
440	Androgen receptor variation affects prostate cancer progression and drug resistance. <i>Pharmacological Research</i> , <b>2016</b> , 114, 152-162	10.2	30
439	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4125-4131	2.2	57
438	Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 643-655	4.5	23
437	Targeted PI3K inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 204-6	4.6	3
436	Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1083-90	4.7	39
435	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1119-21	4.6	3

434	Dual targeting of the androgen receptor and hypoxia-inducible factor 1 $\beta$ pathways synergistically inhibits castration-resistant prostate cancer cells. <i>Molecular Pharmacology</i> , <b>2015</b> , 87, 1006-12	4.3	41
433	Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. <i>Urology</i> , <b>2015</b> , 85, 616-20	1.6	5
432	Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1 $\beta$ . <i>Journal of the American Chemical Society</i> , <b>2015</b> , 137, 5569-75	16.4	29
431	Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 603-10	3	14
430	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1724-33	11.5	48
429	A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 154-61	3.8	24
428	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2228-37	6.1	25
427	Epigenetic approaches to overcoming chemotherapy resistance. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1013-1015	15.7	8
426	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1014-8	4.6	9
425	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2015</b> , 116, 546-55	5.6	45
424	Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 74-82	2.2	394
423	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 122	5.3	20
422	New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1702-3	4.6	
421	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 746-54	13.4	224
420	A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 453-61	5.3	33
419	Effect of 5 $\alpha$ -Reductase Inhibitor Use on Mortality From Prostate Cancer. <i>JAMA Oncology</i> , <b>2015</b> , 1, 321-2	13.4	5
418	Inhibition of the HIF1 $\beta$ -p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). <i>European Journal of Medicinal Chemistry</i> , <b>2015</b> , 94, 509-16	6.8	27
417	Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 201-3	4.6	

416	Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126672	3.7	23
415	Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. <i>Southern Medical Journal</i> , <b>2015</b> , 108, 224-8	0.6	11
414	Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. <i>Current Pharmaceutical Biotechnology</i> , <b>2015</b> , 16, 553-63	2.6	3
413	Statin drug use is not associated with prostate cancer risk in men who are regularly screened. <i>Journal of Urology</i> , <b>2014</b> , 192, 379-84	2.5	37
412	Pharmacologic biomarkers in the development of stratified cancer medicine. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2525-9	12.9	7
411	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 970, 95-101	3.2	6
410	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , <b>2014</b> , 155, 176-87	9	51
409	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju089	9.7	135
408	Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1 $\alpha$ /p300 complex in a preclinical model of prostate cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 91	42.1	52
407	Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 865-73	2.9	25
406	Integrating pharmacogenetic information and clinical decision support into the electronic health record. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2014</b> , 21, 522-8	8.6	46
405	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 446-56	11.2	13
404	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 31.e25-33	2.8	13
403	Multiparametric MRI in prostate cancer management. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 346-53	19.4	97
402	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , <b>2014</b> , 4, 153-162		
401	Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression. <i>Journal of Computer Assisted Tomography</i> , <b>2014</b> , 38, 565-7	2.2	4
400	Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. <i>PLoS ONE</i> , <b>2014</b> , 9, e95532	3.7	19
399	A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application. <i>Chromatography (Basel)</i> , <b>2014</b> , 1, 82-95		11

398	BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1583-5	4.6	21
397	Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1117-9	4.6	2
396	Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1586-7	4.6	13
395	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 955-67	3.5	15
394	Potential novel role of bevacizumab in glioblastoma and cervical cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1296-8	4.6	2
393	New mechanism of lenalidomide activity. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 968-9	4.6	1
392	The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 16-8	4.6	1
391	The role of MRI in prostate cancer active surveillance. <i>BioMed Research International</i> , <b>2014</b> , 2014, 203906		21
390	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5392-402	12.9	71
389	An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5918-26	12.9	50
388	Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1293-5	4.6	3
387	Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5652-62	12.9	23
386	A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 92, 63-8	3.5	18
385	Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. <i>Urology</i> , <b>2014</b> , 84, 127-31	1.6	6
384	Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , <b>2014</b> , 124, 2080-2080	2.2	1
383	Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities. <i>Blood</i> , <b>2014</b> , 124, 2105-2105	2.2	9
382	Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study. <i>Blood</i> , <b>2014</b> , 124, 4746-4746	2.2	4
381	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , <b>2014</b> , 5, 8161-72	3.3	26



380	Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2014</b> , 19, 16-24	1.6	10
379	Pharmacogenetics of membrane transporters: a review of current approaches. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1175, 91-120	1.4	14
378	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5074-5074	2.2	
377	Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16036-e16036	2.2	
376	Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects. <i>Blood</i> , <b>2014</b> , 124, 3476-3476	2.2	
375	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 211-211	2.2	
374	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 218-218	2.2	
373	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 229-37	3.3	20
372	Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 10-9	3.3	12
371	A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 714-23	4.3	23
370	A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2013</b> , 942-943, 107-12	3.2	1
369	BCRP (ABCG2) <b>2013</b> , 311-343		2
368	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 299-307	7.4	50
367	A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2013</b> , 927, 142-6	3.2	6
366	Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?. <i>BMJ Open</i> , <b>2013</b> , 3,	3	5
365	Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. <i>Cancer Prevention Research</i> , <b>2013</b> , 6, 91-9	3.2	24
364	Phase I trial of a new schedule of romidepsin in patients with advanced cancers. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4499-507	12.9	51
363	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E1083-91	11.5	134

362	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2013</b> , 111, 1269-80	5.6	38
361	Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3095-104	12.9	39
360	Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. <i>Biomarkers in Medicine</i> , <b>2013</b> , 7, 831-41	2.3	10
359	Monitor tumor burden with circulating tumor DNA. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 697-8	4.6	14
358	Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E4820	11.5	5
357	Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 90-1	4.6	23
356	Uncovering the genetic landscape driving castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 399-400	4.6	6
355	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 12703-8	11.5	47
354	Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 1005-6	4.6	15
353	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik $\beta$ mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 476-84	2.2	46
352	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 1-8	1.9	107
351	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 10588-10588	2.2	2
350	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 314-314	2.2	6
349	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 128-128	2.2	1
348	A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS5095-TPS5095	2.2	1
347	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4543-4543	2.2	1
346	Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 62, 140-8	3.5	26
345	Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 90-7	4.3	4

344	Preformulation study of NSC-726796. <i>AAPS PharmSciTech</i> , <b>2012</b> , 13, 661-73	3.9	1
343	Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2099-107	12.9	94
342	A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2012</b> , 880, 132-9	3.2	42
341	A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4820-9	12.9	141
340	Associations of serum sex steroid hormone and 5 $\alpha$ -androstane-3 $\alpha$ -7 $\beta$ -diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1823-32	4	13
339	Aflibercept in pediatric solid tumors: moving beyond the trap. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4868-71	12.9	1
338	Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 237-8	4.6	2
337	Angiogenesis inhibitors increase tumor stem cells. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 586-7	4.6	10
336	Significant addition to treatment options for bone metastasis in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 69-70	4.6	4
335	How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 1141-2	4.6	1
334	Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 1374-5	4.6	4
333	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2344-51	12.9	128
332	Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. <i>Oncologist</i> , <b>2012</b> , 17, 312-20	5.7	21
331	Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4671-4671	2.2	1
330	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 207-207	2.2	5
329	Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 64-64	2.2	3
328	Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. <i>Anticancer Research</i> , <b>2012</b> , 32, 2391-8	2.3	3
327	Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. <i>Discovery Medicine</i> , <b>2012</b> , 13, 19-34	2.5	38

326	Disruption of the HIF-1 $\alpha$ /p300 interaction as a means of inhibiting angiogenesis. <i>FASEB Journal</i> , <b>2012</b> , 26, 613-3	0.9	
325	Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3042-3042	2.2	
324	Expression of OATP family members in hormone-related cancers: potential markers of progression. <i>PLoS ONE</i> , <b>2011</b> , 6, e20372	3.7	81
323	Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. <i>PLoS ONE</i> , <b>2011</b> , 6, e14504	3.7	88
322	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. <i>Blood</i> , <b>2011</b> , 117, 4787-95	2.2	127
321	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , <b>2011</b> , 117, 5827-34	2.2	368
320	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 294-305	3.8	100
319	The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2011</b> , 708, 21-7	3.3	25
318	Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. <i>Cancer Causes and Control</i> , <b>2011</b> , 22, 1121-31	2.8	35
317	A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 569-80	12.9	122
316	Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1 $\alpha$ in advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5123-31	12.9	90
315	Estrogen receptor $\beta$ and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, E368-72	5.6	23
314	Impact of ABCB1 allelic variants on QTc interval prolongation. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 937-46	12.9	15
313	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 907-17	12.9	188
312	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. <i>Chemotherapy Research and Practice</i> , <b>2011</b> , 2011, 715469	0	9
311	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e147-e147	2.2	2
310	Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3388-97	12.9	45
309	CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 11, 549-51	4.6	10

308	Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 2284-92	1.9	17
307	A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6831-9	12.9	96
306	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2565-73	2.2	134
305	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 256-67	4.5	65
304	More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. <i>BJU International</i> , <b>2010</b> , 105, 913-6	5.6	12
303	A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. <i>Therapeutics and Clinical Risk Management</i> , <b>2010</b> , 6, 579-83	2.9	31
302	Disclosing a diagnosis of cancer: where and how does it occur?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3630-5	2.2	35
301	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2070-6	2.2	126
300	Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 13-8	4.6	29
299	Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. <i>Cancer Prevention Research</i> , <b>2010</b> , 3, 1523-33	3.2	19
298	Angiogenesis inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 233-47	4	29
297	Sarcosine as a potential prostate cancer biomarker and therapeutic target. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 341-2	4.6	16
296	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 997-1008	3.5	175
295	Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1698-705	9.7	36
294	Androgen receptor sequence and variations in several common prostate cancer cell lines. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 383-8	4.6	3
293	Prostate cancer genomic signature offers prognostic value. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 1079-806	4.6	5
292	A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 583-4	4.6	7
291	Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 1233-4	4.6	6

290	Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 163-5	4.6	1
289	Genetic variant associated with aggressive not indolent prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 957-8	4.6	2
288	Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 38-43	4.6	28
287	Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPC. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 1043-5	4.6	2
286	Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. <i>Annals of Pharmacotherapy</i> , <b>2010</b> , 44, 1709-17	2.9	14
285	Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. <i>Journal of Urology</i> , <b>2010</b> , 184, 2297-302	2.5	34
284	Survivin is not induced by novel taxanes. <i>Molecular Pharmaceutics</i> , <b>2010</b> , 7, 2216-23	5.6	3
283	Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 89-103	2.6	61
282	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2010</b> , 29, 95	12.8	77
281	A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. <i>Journal of Urology</i> , <b>2010</b> , 183, 2219-26	2.5	27
280	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. <i>American Journal of Therapeutics</i> , <b>2010</b> , 17, 176-81	1	6
279	A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 383-9	3.5	21
278	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2010</b> , 878, 3187-92	3.2	1
277	Pharmacogenetics of membrane transporters: an update on current approaches. <i>Molecular Biotechnology</i> , <b>2010</b> , 44, 152-67	3	86
276	Angiogenesis inhibitors: current strategies and future prospects. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2010</b> , 60, 222-43	220.7	350
275	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , <b>2010</b> , 10, 511	4.8	38
274	Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. <i>Prostate</i> , <b>2010</b> , 70, 584-90	4.2	14
273	Phase I study of oral lenalidomide in patients with refractory metastatic cancer. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 650-60	2.9	45

272	Private Practice Administrative Costs Influenced by Insurance Payer Mix. <i>Journal of Oncology Practice</i> , <b>2009</b> , 5, 291-297	3.1	2
271	A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 1800-5	4.6	6
270	Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4292-8	12.9	40
269	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1411-6	12.9	118
268	A genomic strategy for predicting androgen receptor activity in prostate tumors. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2002-3	4.6	1
267	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1496-503	12.9	57
266	Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 26831-8	5.4	130
265	Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5410-7	2.2	601
264	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1143-6	7.5	9
263	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2009</b> , 103, 1636-40	5.6	102
262	Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 355-9	3.2	4
261	The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2496-508	6.1	139
260	Reversal of docetaxel resistance with bevacizumab and thalidomide. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E37-8	3.3	5
259	Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2807-13		131
258	Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. <i>Cancer Investigation</i> , <b>2009</b> , 27, 221-6	2.1	102
257	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 8573-8	11.5	178
256	A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. <i>Journal of Urology</i> , <b>2009</b> , 181, 1104-13; discussion 1113	2.5	33
255	shRNA technology: investigating Ras-dependent cancer. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 1798-9	4.6	3

254	Secondary hormonal therapy for prostate cancer: what lies on the horizon?. <i>BJU International</i> , <b>2008</b> , 101, 271-4	5.6	19
253	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. <i>BJU International</i> , <b>2008</b> , 101, 884-8	5.6	21
252	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , <b>2008</b> , 102, 617-21	5.6	57
251	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. <i>BJU International</i> , <b>2008</b> , 102, 1694-9	5.6	21
250	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , <b>2008</b> , 54, 1089-94	10.2	106
249	Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. <i>Journal of Urology</i> , <b>2008</b> , 179, 2181-5; discussion 2185-6	2.5	91
248	Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial. <i>Urology</i> , <b>2008</b> , 71, 967-70	1.6	6
247	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1148-59	2.2	1651
246	Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 19-26	6.1	70
245	Validation of analytic methods for biomarkers used in drug development. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5967-76	12.9	174
244	Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 872-83	4.3	10
243	Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3312-8	12.9	155
242	Clinical and molecular responses in lung cancer patients receiving Romidepsin. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 188-98	12.9	106
241	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4543-9	12.9	117
240	Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 1180-1	4.6	1
239	Genetic stability of tumor microenvironment. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 331-2	4.6	3
238	Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 1386-7	4.6	4
237	Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 412-5	4.6	8



236	Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. <i>Journal of Chromatographic Science</i> , <b>2008</b> , 46, 356-61	1.4	12
235	Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. <i>Cancer Research</i> , <b>2008</b> , 68, 9996-10003	10.1	122
234	A phase II clinical trial of sorafenib in androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 209-14	12.9	151
233	Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4200-5	12.9	177
232	The genetics of castration-resistant prostate cancer: what can the germline tell us?. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4691-3	12.9	16
231	Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 1246-50	6.1	27
230	Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 1004-5	4.6	27
229	Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 275-81	2.4	18
228	Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 865, 153-8	3.2	11
227	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 862, 213-8	3.2	44
226	Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2008</b> , 46, 362-7	3.5	49
225	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. <i>Blood</i> , <b>2008</b> , 112, 1568-1568	2.2	7
224	Hormone-refractory prostate cancer: where are we going?. <i>Drugs</i> , <b>2007</b> , 67, 1109-24	12.1	13
223	Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. <i>Journal of Pharmaceutical Sciences</i> , <b>2007</b> , 96, 1821-31	3.9	26
222	CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , <b>2007</b> , 96, 2224-31	3.9	74
221	Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 858, 302-6	3.2	4
220	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , <b>2007</b> , 99, 525-8	5.6	6
219	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , <b>2007</b> , 99, 1047-55	5.6	41

218	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. <i>BJU International</i> , <b>2007</b> , 100, 1245-8	5.6	
217	Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. <i>European Urology</i> , <b>2007</b> , 52, 1020-7	10.2	13
216	A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7101-6	12.9	61
215	Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5183-94	12.9	250
214	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5411-7	12.9	107
213	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , <b>2007</b> , 109, 2781-90	2.2	253
212	ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 563-8	2.4	17
211	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 111-26	2.4	50
210	Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 318-9	4.6	
209	Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. <i>Urology</i> , <b>2007</b> , 70, 217-20	1.6	24
208	Thalidomide analogues as anticancer drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2007</b> , 2, 167-74	4.6	55
207	Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2006</b> , 57, 275-81	3.5	35
206	Scientific collaboration results in higher citation rates of published articles. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 759-67	5.8	149
205	Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. <i>Cancer</i> , <b>2006</b> , 106, 63-7	6.4	30
204	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 22-7	4.6	119
203	Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1443-4	4.6	3
202	Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 840-1	4.6	1
201	DNA microarrays: tissue removal and processing affects gene expression. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1608-9	4.6	

200	ETS-TMPRSS2 fusion gene products in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 254-5	4.6	14
199	Randomized discontinuation trial of sorafenib (BAY 43-9006). <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1270-7	4.6	5
198	Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , <b>2006</b> , 4, 331-344		5
197	Thalidomide metabolism and hydrolysis: mechanisms and implications. <i>Current Drug Metabolism</i> , <b>2006</b> , 7, 677-85	3.5	65
196	Influence of garlic ( <i>Allium sativum</i> ) on the pharmacokinetics of docetaxel. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4636-40	12.9	66
195	Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5777-85	12.9	191
194	Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4331-8	12.9	63
193	Lysyl oxidase (LOX) and hypoxia-induced metastases. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 909-11	4.6	20
192	Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. <i>Current Neuropharmacology</i> , <b>2006</b> , 4, 165-72	7.6	185
191	Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation. <i>Current Cancer Therapy Reviews</i> , <b>2006</b> , 2, 223-229	0.4	1
190	The role of drug-metabolising enzymes in clinical responses to chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2006</b> , 2, 17-25	5.5	4
189	Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3502-9	12.9	14
188	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 15-25	9.7	233
187	Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. <i>Molecular Cancer Research</i> , <b>2006</b> , 4, 135-50	6.6	126
186	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 2893-6	7.5	135
185	Pharmacogenetics of irinotecan metabolism and transport: an update. <i>Toxicology in Vitro</i> , <b>2006</b> , 20, 163-75	3.5	146
184	The use of thalidomide in androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 246-9	2.8	12
183	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. <i>Blood</i> , <b>2006</b> , 108, 4126-35	3.5	25

182	The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 1094-5	4.6	1
181	Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 977-83	2.4	7
180	A working group classification of focal prostate atrophy lesions. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1281-91	6.7	97
179	Epidemiology of drug interactions in cancer patients. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 824-824	31.3	
178	Drug interactions in cancer therapy. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 546-58	31.3	224
177	The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 1-8	6.1	7
176	Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 192-201	6.1	105
175	Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2006</b> , 838, 35-40	3.2	8
174	Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 367-75	4.3	18
173	Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.. <i>Blood</i> , <b>2006</b> , 108, 2469-2469	2.2	5
172	A Chiral Pool Approach toward the Synthesis of Thalidomide Metabolites. <i>Heterocycles</i> , <b>2006</b> , 70, 321	0.8	5
171	Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. <i>Oncology Reports</i> , <b>2006</b> , 15, 519-24	3.5	5
170	Prostate cancer - 6th International Congress. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2006</b> , 9, 675-8		
169	Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3465-74	2.2	93
168	Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 555-60	4.6	9
167	Cyclooxygenase-2 and angiogenesis in prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 813-4	4.6	9
166	A phase II study of perifosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1133-7	4.6	88
165	Modulation of cytochrome P450 activity: implications for cancer therapy. <i>Lancet Oncology</i> , <b>2005</b> , 6, 780-9	21.7	94

164	Rational development of histone deacetylase inhibitors as anticancer agents: a review. <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 917-32	4.3	205
163	Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. <i>Urology</i> , <b>2005</b> , 66, 571-6	1.6	13
162	Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutaramide. A metabolite of thalidomide isolated from human plasma. <i>Journal of Organic Chemistry</i> , <b>2005</b> , 70, 10117-20	4.2	31
161	Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 605-11	3.5	20
160	Review of UCN-01 development: a lesson in the importance of clinical pharmacology. <i>Journal of Clinical Pharmacology</i> , <b>2005</b> , 45, 394-403	2.9	83
159	Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2005</b> , 1, 429-45	5.5	111
158	Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer. <i>Nature Reviews Urology</i> , <b>2005</b> , 2, 101-7		16
157	Relationship of systemic exposure to unbound docetaxel and neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 43-53	6.1	68
156	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <i>Pharmacogenomics</i> , <b>2005</b> , 6, 115-38	2.6	100
155	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 985-9	5.6	88
154	Antiangiogenesis: a possible treatment option for prostate cancer?. <i>Clinical Genitourinary Cancer</i> , <b>2005</b> , 4, 197-202	3.3	8
153	Angiogenesis and prostate cancer: important laboratory and clinical findings. <i>Current Oncology Reports</i> , <b>2005</b> , 7, 215-9	6.3	14
152	Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7398-404	12.9	60
151	Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4136-43	12.9	380
150	Molecular alterations in primary prostate cancer after androgen ablation therapy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6823-34	12.9	141
149	Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3912-22	2.2	351
148	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 815-8	4.6	181
147	Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 1222-5	4.6	67

146	Effect of ABCG2 genotype on the oral bioavailability of topotecan. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 650-8	4.6	144
145	Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.. <i>Blood</i> , <b>2005</b> , 106, 1102-1102	2.2	3
144	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. <i>Therapeutics and Clinical Risk Management</i> , <b>2005</b> , 1, 107-14	2.9	55
143	Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 719-20	4.6	13
142	Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 1212-3	4.6	10
141	Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. <i>Expert Opinion on Therapeutic Patents</i> , <b>2004</b> , 14, 215-229	6.8	13
140	Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1585-92	9.7	98
139	Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5038-47	12.9	62
138	Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4192-7	12.9	45
137	A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valsopodar (PSC 833) in renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4724-33	12.9	62
136	Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. <i>Cancer Research</i> , <b>2004</b> , 64, 821-4	10.1	64
135	Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6840-6	12.9	26
134	Immunomodulation of multiple myeloma. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 1060-1	4.6	10
133	hTert-Immortalized Endothelial Cells: An Important New Research Tool. <i>Cell Cycle</i> , <b>2004</b> , 3, 787-787	4.7	1
132	Histone deacetylase inhibitors are potent radiation protectants. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 612-3	4.6	19
131	Genotyping and functional analysis of the D104N variant of human endostatin. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 1298-303	4.6	10
130	Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 503-4	4.6	17
129	Mutations in the EGFR: the importance of genotyping. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 434-5	4.6	7

128	Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2532-9	2.2	276
127	Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 499-506	2.2	77
126	Upregulation of the androgen receptor during prostate cancer progression. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 284-5	4.6	2
125	Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 854-60	2.9	95
124	Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. <i>World Journal of Urology</i> , <b>2004</b> , 22, 425-30	4	11
123	Recent advances in pharmacogenetic approaches to anticancer drug development. <i>Drug Development Research</i> , <b>2004</b> , 62, 233-253	5.1	39
122	Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 804, 289-94	3.2	12
121	Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 805, 135-40	3.2	1
120	Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 806, 289-93	3.2	15
119	Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 806, 305-10	3.2	27
118	Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 809, 81-6	3.2	5
117	Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 2219-27	8.3	44
116	Herbal remedies in the United States: potential adverse interactions with anticancer agents. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2489-503	2.2	346
115	A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 2, 241-3		24
114	Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. <i>Drug Resistance Updates</i> , <b>2004</b> , 7, 195-208	23.2	111
113	Thalidomide. <i>Lancet, The</i> , <b>2004</b> , 363, 1802-11	40	434
112	Anti-Myeloma Activity of Two Novel N-Substituted and Tetrafluorinated Thalidomide Analogues.. <i>Blood</i> , <b>2004</b> , 104, 2406-2406	2.2	
111	Determination of fraction unbound docetaxel using microequilibrium dialysis. <i>Analytical Biochemistry</i> , <b>2004</b> , 331, 192-4	3.1	6

110	Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 811, 135-41	3.2	17
109	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2299-304	2.2	154
108	Luteal phase dose-response relationships of the antiprogesterin CDB-2914 in normally cycling women. <i>Human Reproduction</i> , <b>2003</b> , 18, 1820-7	5.7	29
107	A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. <i>Acta Oncologica</i> , <b>2003</b> , 42, 195-201	3.2	15
106	Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4356-63	2.2	66
105	Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. <i>Anti-Cancer Drugs</i> , <b>2003</b> , 14, 125-35	2.4	23
104	Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 1124-35	2.9	11
103	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2003</b> , 796, 181-8	3.2	43
102	Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 509-10	6.1	10
101	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , <b>2003</b> , 169, 357-360	2.5	16
100	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 153-9		18
99	Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF $\alpha$ -modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 3793-9	8.3	50
98	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , <b>2003</b> , 6, 71-84	23.2	181
97	Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 1369-74	2.9	39
96	Pharmacogenetics of estrogen metabolism and transport in relation to cancer. <i>Current Drug Metabolism</i> , <b>2003</b> , 4, 505-13	3.5	22
95	Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 562-70	12.9	22
94	Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. <i>Cancer Research</i> , <b>2003</b> , 63, 3189-94	10.1	61
93	Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. <i>Molecular Cancer Therapeutics</i> , <b>2003</b> , 2, 845-54	6.1	15



92	Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. <i>Anticancer Research</i> , <b>2003</b> , 23, 3585-90	2.3	16
91	Treatment options for androgen-independent prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2003</b> , 1, 49-57	0.6	20
90	Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 153-9	2.2	123
89	Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2002</b> , 123, 686-94	1.5	35
88	A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. <i>Journal of Experimental Therapeutics and Oncology</i> , <b>2002</b> , 2, 325-32	0.8	170
87	A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. <i>Biomedical Chromatography</i> , <b>2002</b> , 16, 379-82	1.7	8
86	Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. <i>Investigational New Drugs</i> , <b>2002</b> , 20, 183-94	4.3	75
85	Suramin's development: what did we learn?. <i>Investigational New Drugs</i> , <b>2002</b> , 20, 209-19	4.3	57
84	Antiangiogenesis therapeutic strategies in prostate cancer. <i>Cancer and Metastasis Reviews</i> , <b>2002</b> , 21, 93-106	9.6	6
83	Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4074-82	2.2	116
82	Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. <i>Annals of Pharmacotherapy</i> , <b>2002</b> , 36, 905-11	2.9	112
81	The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. <i>Urologia Internationalis</i> , <b>2002</b> , 68, 16-23	1.9	14
80	Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3599-604	2.2	86
79	Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 420-5	4.6	23
78	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. <i>Cancer Biology and Therapy</i> , <b>2002</b> , 1, 669-73	4.6	56
77	5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 104-10	3.2	42
76	Leptomeningeal carcinomatosis in metastatic prostate cancer. <i>Southern Medical Journal</i> , <b>2002</b> , 95, 107-80.6	0.6	4
75	National Cancer Institute intramural approach to advanced prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2002</b> , 1, 153-62		8

74	Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura. <i>Clinical Lung Cancer</i> , <b>2002</b> , 4, 186-92	4.9	13
73	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 718-28	12.9	353
72	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 963-70	12.9	108
71	The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1242-50	12.9	44
70	Thalidomide metabolism by the CYP2C subfamily. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1964-73	12.9	114
69	Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 832-42	2.2	86
68	Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. <i>Biomedical Applications</i> , <b>2001</b> , 759, 247-57		18
67	A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valsopodar). <i>Cancer</i> , <b>2001</b> , 92, 1577-90	6.4	68
66	Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. <i>American Journal of Hematology</i> , <b>2001</b> , 67, 51-3	7.1	19
65	Approaches to preclinical screening of antiangiogenic agents. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 570-6	5.5	38
64	Laparoscopic continuous hyperthermic peritoneal perfusion. <i>Journal of the American College of Surgeons</i> , <b>2001</b> , 193, 225-9	4.4	46
63	Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 800-11	2.2	52
62	Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 584-92	2.2	127
61	Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2319-33	2.2	274
60	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 62-66	5.5	104
59	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. <i>Biomedical Chromatography</i> , <b>2000</b> , 14, 338-43	1.7	13
58	High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2000</b> , 22, 1003-14	3.5	18
57	Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-hydroxyglutamic acid. <i>Tetrahedron Letters</i> , <b>2000</b> , 41, 2275-2278	2	10

56	Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. <i>Tetrahedron Letters</i> , <b>2000</b> , 41, 7151-7155	2	9
55	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 708-15	2.2	377
54	Activity of thalidomide in AIDS-related Kaposi's sarcoma. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2593-602.	2.2	261
53	The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. <i>Oncology Issues</i> , <b>2000</b> , 15, 23-27	0.2	6
52	Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 268, 183-91	3.4	77
51	The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. <i>Journal of Surgical Research</i> , <b>2000</b> , 91, 26-31	2.5	113
50	Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. <i>Microvascular Research</i> , <b>2000</b> , 60, 70-80	3.7	81
49	TNP-470: an angiogenesis inhibitor in clinical development for cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 1383-96	5.9	100
48	EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES. <i>Journal of Urology</i> , <b>2000</b> , 163, 1022-1026	2.5	33
47	A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva <b>2000</b> , 14, 338		1
46	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3461-7	2.2	839
45	A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer. <i>Urologia Internationalis</i> , <b>1999</b> , 63, 120-5	1.9	16
44	Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. <i>Human Gene Therapy</i> , <b>1999</b> , 10, 889-98	4.8	36
43	Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. <i>Journal of Clinical Pharmacology</i> , <b>1999</b> , 39, 394-401	2.9	34
42	A facile scheme for phthalimide ? phthalimidine conversion. <i>Tetrahedron Letters</i> , <b>1999</b> , 40, 2087-2090	2	31
41	Pharmacokinetics of thalidomide in an elderly prostate cancer population. <i>Journal of Pharmaceutical Sciences</i> , <b>1999</b> , 88, 121-5	3.9	87
40	Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 43 Suppl, S78-84	3.5	25
39	Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. <i>Prostate Journal</i> , <b>1999</b> , 1, 99-102		1

38	Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. <i>Mayo Clinic Proceedings</i> , <b>1999</b> , 74, 137-45	6.4	21
37	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1998</b> , 26, 673-87		7
36	Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42 Suppl, S54-9	3.5	72
35	Methods for extracting and amplifying genomic DNA isolated from frozen serum. <i>Nature Biotechnology</i> , <b>1998</b> , 16, 91-4	44.5	36
34	Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. <i>Urology</i> , <b>1998</b> , 52, 252-6	1.6	77
33	Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. <i>Biochemical Pharmacology</i> , <b>1998</b> , 55, 1827-34	6	266
32	UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. <i>Invasion &amp; Metastasis</i> , <b>1998</b> , 18, 209-18		25
31	Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. <i>Annals of Pharmacotherapy</i> , <b>1997</b> , 31, 76-82	2.9	58
30	Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. <i>Journal of Clinical Pharmacology</i> , <b>1997</b> , 37, 123-8	2.9	18
29	An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC. <i>Analytical Letters</i> , <b>1997</b> , 30, 2009-2021	2.2	3
28	Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 32, 368-81	6.2	32
27	In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. <i>Cancer Letters</i> , <b>1997</b> , 113, 111-6	9.9	15
26	New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. <i>Angiogenesis</i> , <b>1997</b> , 1, 23-35	10.6	34
25	Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. <i>Biopharmaceutics and Drug Disposition</i> , <b>1997</b> , 18, 347-59	1.7	6
24	A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. <i>Analytica Chimica Acta</i> , <b>1997</b> , 339, 91-97	6.6	18
23	Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. <i>Cancer Investigation</i> , <b>1996</b> , 14, 513-7	2.1	43
22	Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. <i>Cancer Treatment Reviews</i> , <b>1996</b> , 22, 105-18	14.4	9
21	Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. <i>Acta Oncologica</i> , <b>1996</b> , 35, 763-5	3.2	7

20	Pharmacokinetics of ondansetron in patients with hepatic insufficiency. <i>Journal of Clinical Pharmacology</i> , <b>1996</b> , 36, 206-15	2.9	30
19	Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. <i>American Journal of Hematology</i> , <b>1996</b> , 51, 152-7	7.1	7
18	The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. <i>Prostate</i> , <b>1996</b> , 29, 177-82	4.2	15
17	Mifepristone: antineoplastic studies. <i>Clinical Obstetrics and Gynecology</i> , <b>1996</b> , 39, 498-505	1.7	16
16	Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 714-20	3.2	13
15	Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 412-4	2.4	77
14	A preliminary risk-benefit assessment of paclitaxel. <i>Drug Safety</i> , <b>1995</b> , 12, 196-208	5.1	19
13	Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 368-73	2.9	37
12	Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. <i>American Journal of Cardiology</i> , <b>1995</b> , 76, 1072-3	3	54
11	A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , <b>1995</b> , 75, 2159-64	6.4	36
10	Phase I study of phenylacetate administered twice daily to patients with cancer. <i>Cancer</i> , <b>1995</b> , 75, 2932-8	6.4	101
9	Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. <i>Cancer</i> , <b>1995</b> , 76, 453-62	6.4	60
8	A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>1994</b> , 17, 2895-2900		7
7	Acute renal toxicity associated with suramin in the treatment of prostate cancer. <i>Cancer</i> , <b>1994</b> , 74, 1612-4	6.4	23
6	In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. <i>Anti-Cancer Drugs</i> , <b>1994</b> , 5, 336-42	2.4	7
5	Nitrate tolerance: does tid isosorbide dinitrate mean dosing every eight hours?. <i>DICP: the Annals of Pharmacotherapy</i> , <b>1991</b> , 25, 1272-3		
4	Peripheral neuropathy in HIV patient after isoniazid therapy initiated. <i>DICP: the Annals of Pharmacotherapy</i> , <b>1991</b> , 25, 100-1		9
3	Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. <i>American Journal of Medicine</i> , <b>1988</b> , 85, 452-3	2.4	54

2	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. <i>Novartis Foundation Symposium</i> ,83-102	38
1	Whole or Partial Vessel Outgrowth Assays105-121	1